ZBH: Future Returns Will Depend On U.S. Execution And Ongoing Buybacks

The updated analyst price target for Zimmer Biomet Holdings moves slightly higher to about $103.05, as analysts balance more cautious margin assumptions with modestly stronger long term growth and P/E expectations, alongside mixed recent rating changes and price target revisions across the Street.

Analyst Commentary

Recent Street research on Zimmer Biomet shows a mix of optimism and caution, with views split on how much execution risk and valuation upside remain at current levels.

Bullish Takeaways

Bullish analysts point to what they see as a de risked 2026 outlook, with expectations that potential disruption is already built into longer term forecasts, which can support the current P/E framework used in their models.
Several price target increases in recent research, including a move to about $99 in one case, suggest confidence that the shares can reflect modestly stronger long term growth assumptions over time.
Supportive analysts highlight ongoing commercial changes in the U.S. and prefer to see how execution progresses. They imply that clearer delivery on those initiatives could justify higher valuation multiples.
Some research points to improving sentiment around U.S. healthcare stocks more broadly. If that sentiment is sustained, it could help Zimmer Biomet screen better against sector peers on relative valuation screens.

Bearish Takeaways

Bearish analysts, including Goldman Sachs, flag past deceleration in top line growth and variance versus organic growth estimates as key concerns that still weigh on how they value the shares.
The move from more neutral stances to Sell in recent research reflects a view that current valuation already discounts a return to what those analysts see as more normalized growth patterns.
Some recent price target adjustments lower suggest that, for more cautious analysts, the risk reward looks less compelling if execution on growth initiatives or margin improvement does not track expectations.
Market Perform ratings with no explicit upside case signal a wait and see approach. In that framework, analysts want more evidence on commercial execution before assigning higher growth or P/E assumptions to the stock.

What's in the News

Zimmer Biomet announced a share repurchase program authorizing up to US$1.5b in common stock buybacks, with the stated aim of returning value to shareholders and limiting dilution from stock issuances, and no expiration date on the program.
The Board of Directors authorized an additional buyback plan on February 9, 2026, signaling continued use of repurchases as a capital allocation tool.
Between October 1, 2025 and December 31, 2025, Zimmer Biomet repurchased 2,711,242 shares, representing 1.37% of shares, for US$250m, bringing total repurchases under the May 29, 2024 program to 11,782,424 shares, or 5.83%, for US$1,229.78m.
Summit Health reported the first complete robotic assisted shoulder replacement in a freestanding ambulatory surgery center using Zimmer Biomet’s ROSA Robotics Platform, covering both anatomic and reverse shoulder replacements and using CT based planning with sub millimeter placement variance (Summit Health announcement).
Zimmer Biomet plans to showcase a range of orthopedic technologies at the AAOS 2026 Annual Meeting, including the ROSA Knee with OptimiZe, TMINI Miniature Robotic System, Monogram Technologies TKA System, OrthoGrid Hip AI, Oxford Cementless Partial Knee, Z1 Femoral Hip System and the Persona IQ smart knee, with Chief Movement Officer Arnold Schwarzenegger scheduled as Presidential Guest Speaker (AAOS 2026 meeting announcement).

Valuation Changes

Fair Value: Updated slightly higher to about $103.05 from $103, a move of less than 1%.
Discount Rate: Adjusted modestly higher to roughly 8.78% from 8.72%, implying a small increase in the required return used in the models.
Revenue Growth: Assumed long term revenue growth edges up to around 3.65% from 3.62%, a minimal change.
Net Profit Margin: Long term net profit margin assumption is trimmed to about 12.71% from 13.24%, a reduction of roughly 0.53 percentage points.
Future P/E: Forward P/E multiple moves higher, with the assumption rising to about 21.52x from 20.64x.

3 views

Key Takeaways

Expanding into high-growth segments and leveraging digital health and robotics is boosting recurring revenue, premium product adoption, and margin expansion.
Operational efficiencies, divestitures, and strong US execution are driving improved cash flow and above-market share gains in core orthopedic categories.
Rising pricing pressures, regulatory uncertainties, and execution risks from acquisitions and innovation may hinder Zimmer Biomet's market position, margin stability, and overall growth potential.

Catalysts

About Zimmer Biomet Holdings

Operates as a medical technology company worldwide.What are the underlying business or industry changes driving this perspective?

The growing global elderly population and the rise in chronic lifestyle diseases are expected to accelerate procedure volumes for orthopedic implants and joint replacements, positioning Zimmer Biomet for long-term sustained revenue growth as demand structurally expands.
Strategic acquisitions-such as Monogram Technologies and Paragon 28-are diversifying Zimmer Biomet into higher-growth market segments and introducing innovative, AI-driven robotics, which is projected to enhance future top-line growth and support higher returns on invested capital from 2027 onwards.
The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.
Operational improvements, supply chain efficiencies, and ongoing portfolio optimization-including divestiture of non-core businesses and disciplined cost management-are resulting in better-than-expected free cash flow generation and improving adjusted net margins even amidst integration expenses from recent M&A.
Zimmer Biomet's strengthened US commercial execution, focus on ambulatory surgery center (ASC) growth, strong pipeline of new product launches, and successful integration of acquired commercial channels are expected to sustain above-market share gains in hips, knees, and extremities, driving organic revenue growth and improved earnings quality over the next several years.

Zimmer Biomet Holdings Earnings and Revenue Growth

Zimmer Biomet Holdings Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Zimmer Biomet Holdings's revenue will grow by 3.6% annually over the next 3 years.
Analysts assume that profit margins will increase from 8.6% today to 12.7% in 3 years time.
Analysts expect earnings to reach $1.2 billion (and earnings per share of $6.02) by about April 2029, up from $705.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.5 billion in earnings, and the most bearish expecting $852.4 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 21.5x on those 2029 earnings, down from 25.5x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.3x.
Analysts expect the number of shares outstanding to decline by 1.11% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.78%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Ongoing industry-wide pricing pressures and potential reimbursement challenges, as evidenced by the company's expectation for selling prices to be roughly flat for the full year, could limit future revenue growth and compress net margins over time.
Increasing competitive intensity, particularly from established players like Stryker (who claim to already possess fully autonomous robotic capabilities), may erode Zimmer Biomet's market share in robotics and core orthopedics, threatening long-term revenue growth and profit sustainability.
Heavy reliance on successful integration and commercialization of recent acquisitions (e.g., Paragon 28 and Monogram Technologies), with admissions that acquisitions have led to a decline in year-over-year operating margins and increased leverage, may introduce risks of execution failures or delayed synergies, negatively impacting both earnings and free cash flow.
Uncertainty around regulatory timelines for disruptive technologies, highlighted by management's cautious language about clinical trials and FDA pathways for fully autonomous robotics, could delay new product launches and slow revenue contributions from these platforms well into the latter half of the decade.
Global tariff exposure and macroeconomic risks, while mitigated for the current year, are described as "fluid" and could worsen unexpectedly in the future (especially with changing global trade dynamics), raising costs and threatening both operating profit and future earnings stability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $103.05 for Zimmer Biomet Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $130.0, and the most bearish reporting a price target of just $88.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $9.2 billion, earnings will come to $1.2 billion, and it would be trading on a PE ratio of 21.5x, assuming you use a discount rate of 8.8%.
Given the current share price of $93.03, the analyst price target of $103.05 is 9.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Zimmer Biomet Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Aging Population And Robotics Will Elevate Orthopedic Care